Xylo Bio Achieves Clinical-Stage Milestone with XYL-1001, a Highly Selective Neuroplastogen Targeting Major Depressive Disorder

Xylo Bio announced that the first participants have been dosed in its Phase 1 trial of XYL-1001, a selective 5-HT2A agonist being developed for psychiatric and neurological disorders. The milestone advances the clinical-stage company’s neurotherapeutics pipeline into initial human testing, but no efficacy, safety, financial, or commercial data were disclosed.